Key result
Infective endocarditis in pregnancy shows no difference in maternal mortality compared to non-pregnant women.
Why the study?
Infective endocarditis in pregnancy is increasing while pregnancy obscures presentation and constrains diagnosis and treatment, and the evidence remains scattered across case reports, small series, and retrospective cohorts.
Does infective endocarditis in pregnancy alter maternal mortality, morbidity, and management outcomes compared to non-pregnant women?
Does infective endocarditis in pregnancy alter maternal mortality, morbidity, and management outcomes compared to non-pregnant women?
Answers are grounded in this paper and cite their sources.
Infective endocarditis in pregnancy does not significantly increase in-hospital maternal mortality compared to non-pregnant women except when complicating the delivery admission, but requires specialized multidisciplinary care, pregnancy-compatible antimicrobials, and coordinated timing of delivery and valve surgery to mitigate high fetal mortality and maternal morbidity.
Infective endocarditis (IE) in pregnancy is rare (incidence about 0.006%) but increasing, driven by injection drug use, prosthetic valves and cardiac devices, and more women with congenital heart disease reaching reproductive age. Pregnancy obscures presentation and constrains diagnosis and treatment, and the evidence is scattered across case reports, small series and retrospective cohorts. This narrative review synthesizes published case reports, case series, cohort studies and reviews on IE in pregnancy and the postpartum period, focusing on maternal outcomes, risk factors, diagnosis and management, with fetal outcomes as a secondary consideration. Risk factors include injection drug use, rheumatic and congenital heart disease, prosthetic valves and intracardiac devices; Staphylococcus aureus predominates. Physiological murmurs, atypical symptoms and other febrile illnesses delay diagnosis. Contemporary maternal in-hospital mortality is 5-17% and, in the two largest comparative datasets, did not differ significantly from that of non-pregnant women. IE diagnosed during the delivery admission is the exception, with 17.2% mortality and severe morbidity in 77.5%. Heart failure, septic embolization and arrhythmia dominate morbidity. Valve surgery rates are similar to those in non-pregnant patients; bypass during pregnancy yields excellent maternal survival but 18-20% fetal mortality, favoring cesarean delivery followed by valve surgery once the fetus is viable. Multidisciplinary care, including addiction medicine, was associated with fewer patient-directed discharges. IE in pregnancy mainly alters recognition and management rather than survival of established disease, except at delivery. Early suspicion, echocardiography, blood cultures, pregnancy-compatible antimicrobials, timing of delivery and surgery, and tertiary multidisciplinary care are central. Prospective registries are needed.
No takes yet. Share an insight, caveat, or question.
Deraiya et al. (2026) conducted a review in Infective endocarditis in pregnancy and the postpartum period. Pregnancy-associated infective endocarditis vs. Non-pregnancy-associated infective endocarditis in women of reproductive age was evaluated on Maternal in-hospital mortality (in the largest comparative national database cohort of 382 maternity-associated IE hospitalizations) (aRR 1.03, 95% CI 0.71-1.48). Infective endocarditis in pregnancy carries 5-17% maternal in-hospital mortality, not differing from non-pregnant women, except at delivery.
Synapse has enriched 10 related papers. Consider them for comparative context: